Metabolism and Target Organ Damage

A Special Interview with Prof. Huiping Zhou, Editorial Board Member of M&TOD

Tenured Professor and Chair of the Department of Microbieology and Immunology at Virginia Commonwealth University, Richmeond, VA USA

M&TOD Accepted for Inclusion in Emerging Sources Citation Index (ESCI) in June 2024

The journal will receive its first impact factor in June 2025, and all published papers will be comprehensively indexed in the Web of Science Core Collection.

Exclusive Interview with Dr. Robert Wong from Stanford University School of Medicine

Dr. Robert Wong is a Fellow of the American College of Gastroenterology (ACG).

Congratulations! Metabolism and Target Organ Damage Achieves a First CiteScore of 3.0

CiteScore, a metric provided by Elsevier, gauges the average number of citations garnered per document published in a journal over a four-year span.

Introducing our new preprint platform, a fast and efficient way to share your research with the academic community.

We consistently welcome suggestions for improvements from both readers and authors (send an e-mail to preprint@scierxiv.com).

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Sarcopenia in the setting of nonalcoholic fatty liver

Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms

Pre-onlines

Role of skin enzymes in metabolism of topical drugs

Copper and liver fibrosis in MASLD: the two-edged sword of copper deficiency and toxicity

Articles

Most Recent | Most Viewed | Most Downloaded

Dysregulation of sphingolipid metabolism in liver fibrosis

Nan Wu, ... Huiping Zhou

Open Access Review DOI: 10.20517/mtod.2024.38 13 Sep 2024

Views: Downloads:

Download PDF

From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction

Stefano Ciardullo

, Gianluca Perseghin

Open Access Review DOI: 10.20517/mtod.2024.39 27 Aug 2024

Views: Downloads:

Download PDF

Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review

Matthew L. Basa, ... Daniel L. Chan

Open Access Review DOI: 10.20517/mtod.2024.22 25 Aug 2024

Views: Downloads:

Download PDF

Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis

Lucas M. Marks, ... Timothy R. DeGrado

Open Access Review DOI: 10.20517/mtod.2024.44 21 Aug 2024

Views: Downloads:

Download PDF

Editorial - Reflecting on three years of M&TOD - Where we are and where we are going

Amedeo Lonardo

Open Access Editorial DOI: 10.20517/mtod.2024.65 13 Aug 2024

Views: Downloads:

Download PDF

Most Cited Papers In Last Two Years

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Amedeo Lonardo

, ... Kusum K. Kharbanda

Open Access Perspective DOI: 10.20517/mtod.2022.14 21 Aug 2022

Views: Downloads:

Download PDF

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Stefano Ballestri

, ... Amedeo Lonardo

Open Access Review DOI: 10.20517/mtod.2022.23 30 Jan 2023

Views: Downloads:

Download PDF

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Amedeo Lonardo

, Gjin Ndrepepa

Open Access Review DOI: 10.20517/mtod.2022.20 29 Sep 2022

Views: Downloads:

Download PDF

Webinars

Ongoing Special Issues

Topic: Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

Assoc. Prof. Gyorgy Baffy; Prof. Amedeo Lonardo; Prof. Ralf Weiskirchen

Submission Deadline: 30 Jun 2025

Published articles: 2

Topic: Hypertension and Metabolic Disorders: Pathophysiology, Clinical Management, and Novel Therapeutic Approaches

Prof. Xingjiang Xiong; Prof. Pengqian Wang; Prof. Wei Liu; Dr. Lian Duan

Submission Deadline: 31 Mar 2025

Published articles: 0

Editorial Board

Partners

Data

356

Authors

255

Reviewers

Articles

On Board Editors

2021

Published Since

For Authors

For Reviewers

Peer Review Guidelines

For Readers

Add your e-mail address to receive forthcoming Issues of this journal:

Topics Collection

Topic: Organ Dysfunction in Metabolic-Associated Fatty Liver Disease: Effect of Cofactors

Topic: The Latest Research Progress of Nonalcoholic Fatty Liver Disease

Topic: The Complications of Diabetes

Metabolism and Target Organ Damage Accepted for Inclusion in Emerging Sources Citation Index (ESCI) in August 2024!

Congratulations! Metabolism and Target Organ Damage Achieves a First CiteScore of 3.0

A Special Interview with Prof. Huiping Zhou, Editorial Board Member of M&TOD

Tenured Professor and Chair of the Department of Microbieology and Immunology at Virginia Commonwealth University, Richmeond, VA USA

M&TOD Accepted for Inclusion in Emerging Sources Citation Index (ESCI) in June 2024

The journal will receive its first impact factor in June 2025, and all published papers will be comprehensively indexed in the Web of Science Core Collection.

Exclusive Interview with Dr. Robert Wong from Stanford University School of Medicine

Dr. Robert Wong is a Fellow of the American College of Gastroenterology (ACG).

Congratulations! Metabolism and Target Organ Damage Achieves a First CiteScore of 3.0

CiteScore, a metric provided by Elsevier, gauges the average number of citations garnered per document published in a journal over a four-year span.

Introducing our new preprint platform, a fast and efficient way to share your research with the academic community.

We consistently welcome suggestions for improvements from both readers and authors (send an e-mail to preprint@scierxiv.com).

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Topic: Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

Assoc. Prof. Gyorgy Baffy; Prof. Amedeo Lonardo; Prof. Ralf Weiskirchen

Submission Deadline: 30 Jun 2025

Published articles: 2

Topic: Hypertension and Metabolic Disorders: Pathophysiology, Clinical Management, and Novel Therapeutic Approaches

Prof. Xingjiang Xiong; Prof. Pengqian Wang; Prof. Wei Liu; Dr. Lian Duan

Submission Deadline: 31 Mar 2025

Published articles: 0

News

Metabolism and Target Organ Damage Accepted for Inclusion in Emerging Sources Citation Index (ESCI) in August 2024!

Congratulations! Metabolism and Target Organ Damage Achieves a First CiteScore of 3.0

Data

356

Authors

255

Reviewers

Articles

On Board Editors

2021

Published Since

Metabolism and Target Organ Damage

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Sarcopenia in the setting of nonalcoholic fatty liver

Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms

Role of skin enzymes in metabolism of topical drugs

Copper and liver fibrosis in MASLD: the two-edged sword of copper deficiency and toxicity

Articles

Dysregulation of sphingolipid metabolism in liver fibrosis

From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction

Metabolic bariatric surgery, alcohol misuse and liver cirrhosis: a narrative review

Noninvasive testing in the diagnosis of metabolic dysfunction-associated steatohepatitis

Editorial - Reflecting on three years of M&TOD - Where we are and where we are going

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Topic: Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

Topic: Hypertension and Metabolic Disorders: Pathophysiology, Clinical Management, and Novel Therapeutic Approaches

Effect of cofactors on NAFLD/NASH and MAFLD - a paradigm illustrating the pathomechanics of organ dysfunction

Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality

Concise review: gamma-glutamyl transferase - evolution from an indiscriminate liver test to a biomarker of cardiometabolic risk

Sarcopenia in the setting of nonalcoholic fatty liver

Metabolic primary liver cancer in adults: risk factors and pathogenic mechanisms

Role of skin enzymes in metabolism of topical drugs

Copper and liver fibrosis in MASLD: the two-edged sword of copper deficiency and toxicity

Topic: Liver Fibrosis in Metabolic Dysfunction: Cellular and Molecular Mechanisms, Innovative Diagnostics, and Emerging Therapeutic Approaches

Topic: Hypertension and Metabolic Disorders: Pathophysiology, Clinical Management, and Novel Therapeutic Approaches

Metabolism and Target Organ Damage Accepted for Inclusion in Emerging Sources Citation Index (ESCI) in August 2024!

Congratulations! Metabolism and Target Organ Damage Achieves a First CiteScore of 3.0

Committee on Publication Ethics

Portico

Committee on Publication Ethics

Portico